Compounded vs Brand-Name GLP-1: Safety, Cost & Efficacy Compared

Compounded vs brand-name GLP-1: quick comparison

What is compounded GLP-1 medication?

Compounded medications are custom-made by compounding pharmacies rather than mass-produced by pharmaceutical manufacturers. Under FDA regulations, compounding pharmacies can produce versions of commercially available drugs when those drugs are on the FDA shortage list.

Since semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) have experienced shortages since 2022, compounding pharmacies have been producing compounded versions. These are typically sold through telehealth programs like NewSelf, Mochi Health, and Hims & Hers.

Safety considerations

Brand-name safety

Wegovy and Zepbound have undergone rigorous FDA premarket review with large clinical trials (STEP, SURMOUNT). Their safety profiles are well-characterized across hundreds of thousands of patients.

Compounded safety

Compounded GLP-1 medications are not FDA-approved and have not undergone premarket review. However, if produced by a licensed US compounding pharmacy following USP standards, they are generally considered safe. Key risks:

• No FDA oversight: Quality may vary between pharmacies
• No clinical trial data: Efficacy and safety not formally studied
• FDA warnings: The FDA has issued warning letters to companies making false equivalence claims or selling unapproved versions
• Salt forms: Some compounding pharmacies previously used semaglutide salts (not the same as the active ingredient in Wegovy). The FDA has banned these.

Always verify: the pharmacy is licensed in your state, the product contains semaglutide (not a salt form), and your provider is monitoring your progress.

Cost comparison

Full pricing details in our GLP-1 Cost Guide 2026, Wegovy cost guide, and Zepbound cost guide.

FDA regulations and the future of compounded GLP-1s

The FDA permits compounding of drugs on the shortage list. As of August 2026:

• Most Wegovy doses are back in stock — compounding of semaglutide may be restricted
• Some Ozempic doses remain in shortage — compounding may continue
• Zepbound and Mounjaro availability has improved
• The FDA issued warning letters to 30 telehealth companies in March 2026 for false claims
• Novo Nordisk has taken legal action against clinics using "semaglutide" to market compounded products

See our GLP-1 shortage 2026 update for current availability.

Which should you choose?

Choose brand-name if:

• You want FDA-approved medication with proven safety data
• Your insurance covers Wegovy or Zepbound
• You can access NovoCare pen ($149) or LillyDirect vials ($299-$449)
• You want the assurance of FDA-regulated manufacturing

Choose compounded if:

• You do not have insurance and want the lowest cost
• You are comfortable with a non-FDA-approved product
• You use a reputable telehealth program with a licensed pharmacy
• Brand-name options are unavailable in your area

See our best telehealth GLP-1 guide for provider comparisons.

Related guides

• GLP-1 Cost Guide 2026
• GLP-1 Comparison Guide 2026
• GLP-1 Shortage 2026 Update
• Compounded Semaglutide vs Brand Name
• Affordable Compounded Tirzepatide
• Best GLP-1 Telehealth Programs
• Cheapest GLP-1 Options
• Wegovy Cost Guide
• Zepbound Cost Guide

Medical disclaimer: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting any medication.